Jun 4, 2026 07:01AM
Jun 4, 2026 07:00AM
Apr 22, 2026 07:02AM
Apr 22, 2026 07:00AM
Mar 25, 2026 08:30AM
Dec 11, 2025 07:02AM
Dec 11, 2025 07:00AM BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis
Nov 12, 2025 07:00AM
Aug 13, 2025 08:00AM
Mar 27, 2025 07:00AM
Jan 28, 2025 07:00AM
Apr 14, 2022 07:00AM
Jan 11, 2022 04:06PM
Jan 11, 2022 04:05PM BeyondSpring Announces Organizational Streamlining
Dec 30, 2021 08:02AM
Dec 30, 2021 08:00AM
Dec 10, 2021 08:00AM
Dec 1, 2021 09:32AM
Dec 1, 2021 08:01AM
Dec 1, 2021 08:00AM
Nov 30, 2021 11:08AM BeyondSpring (BYSI) option IV above 300 on more calls than puts
Nov 29, 2021 11:29AM
Nov 24, 2021 05:09AM
Nov 19, 2021 04:04AM
Nov 18, 2021 04:18AM
Nov 17, 2021 02:05PM
Nov 11, 2021 04:26AM
Nov 10, 2021 04:57AM BeyondSpring (BYSI) puts more active than calls
Oct 21, 2021 07:00AM
Oct 20, 2021 07:00AM
Oct 18, 2021 05:16AM
Sep 20, 2021 07:32AM
Sep 20, 2021 07:30AM
Sep 16, 2021 07:04AM
Sep 16, 2021 07:00AM BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
Sep 9, 2021 07:00AM
Aug 31, 2021 07:03AM
Aug 31, 2021 07:00AM
Aug 26, 2021 07:11AM
Aug 26, 2021 07:00AM
Aug 10, 2021 08:00AM
Aug 4, 2021 07:02AM BeyondSpring (BYSI) DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for Treatment of 2nd/3rd Line NSCLC with EGFR Wild Type Met Primary Endpoint
Aug 4, 2021 07:00AM
Jul 14, 2021 07:35AM
Jul 14, 2021 07:30AM
Jun 17, 2021 04:00PM
Jun 17, 2021 06:52AM
Jun 16, 2021 08:00AM
Jun 10, 2021 07:11AM BeyondSpring (BYSI) Announces Final Positive Data from PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at ASCO
Jun 10, 2021 07:00AM

323,564 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All